Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

New Horizons. A New Paradigm for Treating to Target with Second-Generation Obesity Medications
W. Timothy Garvey
The Journal of Clinical Endocrinology & Metabolism (2021) Vol. 107, Iss. 4, pp. e1339-e1347
Open Access | Times Cited: 62

Showing 1-25 of 62 citing articles:

Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
W. Timothy Garvey, Juan P. Frías, Ania M. Jastreboff, et al.
The Lancet (2023) Vol. 402, Iss. 10402, pp. 613-626
Open Access | Times Cited: 317
Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials
Mihaela-Simona Popoviciu, Lorena Păduraru, Galal Yahya, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 13, pp. 10449-10449
Open Access | Times Cited: 103
What is the pipeline for future medications for obesity?
Eka Melson, Uzma Ashraf, Dimitris Papamargaritis, et al.
International Journal of Obesity (2024)
Open Access | Times Cited: 103
The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities
Thomas A. Wadden, Ariana M. Chao, Molly Moore, et al.
Current Obesity Reports (2023) Vol. 12, Iss. 4, pp. 453-473
Open Access | Times Cited: 54
Strengths and Limitations of BMI in the Diagnosis of Obesity: What is the Path Forward?
Katherine Sweatt, W. Timothy Garvey, Cátia Martins
Current Obesity Reports (2024) Vol. 13, Iss. 3, pp. 584-595
Open Access | Times Cited: 34
Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Qiyuan Keith Liu
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 15
Semaglutide delays 4‐hour gastric emptying in women with polycystic ovary syndrome and obesity
Mojca Jensterle, Simona Ferjan, Luka Ležaič, et al.
Diabetes Obesity and Metabolism (2022) Vol. 25, Iss. 4, pp. 975-984
Open Access | Times Cited: 52
Semaglutide (GLP‐1 receptor agonist) stimulates browning on subcutaneous fat adipocytes and mitigates inflammation and endoplasmic reticulum stress in visceral fat adipocytes of obese mice
Fabiane Ferreira Martins, Thatiany de Souza Marinho, Luiz E.M. Cardoso, et al.
Cell Biochemistry and Function (2022) Vol. 40, Iss. 8, pp. 903-913
Closed Access | Times Cited: 42
American Association of Clinical Endocrinology Consensus Statement: Addressing Stigma and Bias in the Diagnosis and Management of Patients with Obesity/Adiposity-Based Chronic Disease and Assessing Bias and Stigmatization as Determinants of Disease Severity
Karl Nadolsky, Brandi Addison, Monica Agarwal, et al.
Endocrine Practice (2023) Vol. 29, Iss. 6, pp. 417-427
Open Access | Times Cited: 25
Anti‐obesity pharmacological agents for polycystic ovary syndrome: A systematic review and meta‐analysis to inform the 2023 international evidence‐based guideline
Alyse S. Goldberg, Sandro Graca, Jing Liu, et al.
Obesity Reviews (2024) Vol. 25, Iss. 5
Open Access | Times Cited: 14
Approach to Obesity Treatment in Primary Care
Susan Z. Yanovski, Jack A. Yanovski
JAMA Internal Medicine (2024) Vol. 184, Iss. 7, pp. 818-818
Closed Access | Times Cited: 11
Managing insulin resistance: the forgotten pathophysiological component of type 2 diabetes
Muhammad Abdul-Ghani, Pietro Maffei, Ralph A. DeFronzo
The Lancet Diabetes & Endocrinology (2024) Vol. 12, Iss. 9, pp. 674-680
Closed Access | Times Cited: 11
Emerging Pharmacotherapies for Obesity: A Systematic Review
Michail Kokkorakis, Marlene Chakhtoura, Caline Rhayem, et al.
Pharmacological Reviews (2024) Vol. 77, Iss. 1, pp. 100002-100002
Open Access | Times Cited: 9
The past, present, and future of behavioral obesity treatment
Ariana M. Chao, Molly Moore, Thomas A. Wadden
International Journal of Obesity (2024)
Closed Access | Times Cited: 8
Cardiometabolic Disease Staging and Major Adverse Cardiovascular Event Prediction in 2 Prospective Cohorts
Carrie R. Howell, Li Zhang, Tapan Mehta, et al.
JACC Advances (2024) Vol. 3, Iss. 4, pp. 100868-100868
Open Access | Times Cited: 7
Association of Baseline Factors With Glycemic Outcomes in GRADE: A Comparative Effectiveness Randomized Clinical Trial
W. Timothy Garvey, Robert M. Cohen, Nicole M. Butera, et al.
Diabetes Care (2024) Vol. 47, Iss. 4, pp. 562-570
Open Access | Times Cited: 6
Therapeutic Potential of Glucagon-like Peptide-1 Agonists in Polycystic Ovary Syndrome: From Current Clinical Evidence to Future Perspectives
Mojca Jensterle, Rok Herman, Andrej Janež
Biomedicines (2022) Vol. 10, Iss. 8, pp. 1989-1989
Open Access | Times Cited: 26
Brown Adipose Tissue: A New Potential Target for Glucagon-like Peptide 1 Receptor Agonists in the Treatment of Obesity
Tim Hropot, Rok Herman, Andrej Janež, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 10, pp. 8592-8592
Open Access | Times Cited: 13
G protein-coupled receptors driven intestinal glucagon-like peptide-1 reprogramming for obesity: Hope or hype?
Mohan Patil, Ilaria Casari, Leon N. Warne, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 172, pp. 116245-116245
Open Access | Times Cited: 5
Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial
Wenhui Qin, Jun Yang, Ying Ni, et al.
Endocrine (2024)
Open Access | Times Cited: 5
Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article
Wael R. Sidrak, Sanjay Kalra, Atul Kalhan
Indian Journal of Endocrinology and Metabolism (2024) Vol. 28, Iss. 5, pp. 445-460
Open Access | Times Cited: 5
Role of Glucagon-Like Peptide-1 Receptor Agonists in People With Infertility and Pregnancy
Johanna Finkle, Brian Brost
Obstetrics and Gynecology (2025)
Closed Access
Real‐world use and effectiveness of tirzepatide among individuals without type 2 diabetes: Results from the Optum Market Clarity database
Emily R. Hankosky, Chanadda Chinthammit, Alexandra Meeks, et al.
Diabetes Obesity and Metabolism (2025)
Open Access
Real-World Use and Effectiveness of Tirzepatide Among People Without Evidence of Type 2 Diabetes in the United States
Emily R. Hankosky, Karishma Desai, Chanadda Chinthammit, et al.
Diabetes & Metabolism (2025), pp. 101636-101636
Open Access
Subclustering general population with high body mass index to inform future risk of diabetes mellitus
Huili Zheng, Chalani Udhyami Ubeynarayana, Serena Kiat Mun Low, et al.
Singapore Medical Journal (2025)
Open Access
Page 1 - Next Page

Scroll to top